Allergan expects solid 2017 under Trump administration; Takeda faces antirust suit & more — 3 GI companies making waves

The following GI companies have made headlines this week, with Japan-based Takeda Pharmaceuticals facing the revival of an antitrust case.

Dublin, Ireland-based Allergan Chief Executive Brent Saunders said the company expects a strong financial outlook for 2017 as Mr. Saunders doesn't believe President Donald Trump will reform any U.S. taxes this year that will negatively impact the company's bottom line.

Allergan reported earnings per share of $3.90 for its fourth quarter, beating analysts' estimates of $3.76 EPS.

Israel-based Motus GI raised $25.6 million in its latest fundraising round with 171 investors contributing to the round. The company still has $4.4 million to raise.

The second circuit court in New York reviewed claims that Takeda Pharmaceuticals delayed a competitor from releasing a generic version of Actos.

Takeda Pharmaceuticals donated $1 million to Cambridge, Mass.-based Koch Institute for integrative cancer research. The Institute is researching the cancer's role in immune response to possibly develop novel treatments.

More articles on gastroenterology/endoscopy:
Pediatric irritable bowel syndrome patients often low in vitamin D: 4 key notes
Can disposable duodenoscopes limit infection risks? 3 insights from an attorney
5 most read GI/endoscopy stories — Feb. 6 to Feb. 10, 2017

© Copyright ASC COMMUNICATIONS 2018. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Top 40 Articles from the Past 6 Months